尊龙时凯

2019/05/16

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

Highlights progress and commitment to deliver breakthrough medicines to meet the needs of patients around the worldPlans to maximize potential of leading brands by filing more than 40 line extensions ...

2017/09/08

[Media Report] Serving In the Name of Progress

In an interview with China Daily, Joaquin Duato, Executive Vice-President and Worldwide Chairman of Pharmaceuticals at Johnson&Johnson

2017/08/30

China Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs

[Beijing], [30 August, 2017] – Xian Janssen Pharmaceutical Ltd.

2017/08/05

Enlightened Light, Blooming Bright -- 14th Johnson & Johnson China World Window on Pediatrics Seminar Draws to a Successful Conclusion

The 14th Johnson & Johnson China World Window on Pediatrics Seminar, co-hosted by Shanghai Johnson & Johnson Pharmaceuticals Ltd. and Xian Janssen Pharmaceutical Ltd., was held on August ...

2016/01/08

ZYTIGA® - New prostate cancer treatment now available to patients across China

January 8, 2016, Beijing – Today, Xian Janssen Pharmaceutical Ltd., announced the launch of ZYTIGA® (abiraterone acetate), a new kind of treatment for men with metastatic castration-resistant prostate...

2015/10/13

Xian Janssen Celebrates 30 Years of Commitment to China

Xi’an, China, 13 October 2015 – Xian-Janssen reaffirmed its commitment to partner with the Chinese Government and invest in healthcare innovation in China during a ceremony celebrating the 30th annive...